A new report from Decision Resources says the number of publicly disclosed biosimilar development projects has risen by 40% in the past 12 months. South American companies had the biggest increase largely driven by Productive Development Partnerships in Brazil. Indian companies have also seen a large increase in public disclosures of projects.
Among developers, monoclonal antibodies, like ritixumab (Rituxan) or trastuzumab (Herceptin) are the most popular targets. This is due to the high sales currently commanded by the reference brands and their coming off patent soon in major markets.
The report also states that there has been a 34% increase in the number of partnerships formed to introduce biosimilars. This is in recognition of the competitiveness of the space and the need to augment internal capability to reach the market faster.
Decision Resources is forecasting that sales of biosimilars in US, Japan, Germany, France, UK, Italy and Spain will exceed $19.5 B by 2022. See Pharma Times.
Posted by Bruce Lehr May 1st 2014.